GNH USA

Europe — EMA

Imlygic

GNH USA supplies Imlygic (Talimogene Laherparepvec), a oncolytic virus therapy for unresectable stage IIIB–IV melanoma. Request a quote for global supply.

Talimogene Laherparepvec

Request sourcing

1
Pack/s

What is Talimogene Laherparepvec?

Talimogene laherparepvec, the active ingredient in Imlygic, is a oncolytic virus therapy presented as a solution for injection for intralesional use. It treats unresectable stage IIIB–IV melanoma in adult patients.

GNH USA supplies Imlygic as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Talimogene Laherparepvec used for?

Imlygic is an oncolytic virus therapy indicated for advanced melanoma.

- Unresectable stage IIIB melanoma: improves local tumor control and may stimulate systemic anti‑tumor immunity. - Unresectable stage IIIC melanoma: reduces tumor burden and can lead to durable responses. - Unresectable stage IV melanoma: provides an immunotherapeutic option when surgery is not feasible.

What are the side effects of Talimogene Laherparepvec?

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Flu‑like symptoms: fever, chills, and fatigue occurring shortly after administration. - Nausea: occasional mild nausea without vomiting. - Headache: transient headache reported by some patients. - Redness or swelling: localized erythema around the injection area.

Serious or Rare Side Effects: - Cellulitis: infection of the skin and subcutaneous tissue requiring medical attention. - Herpetic keratitis: eye infection that can affect vision. - Disseminated viral infection: systemic spread of the virus in immunocompromised individuals. - Severe allergic reaction: anaphylaxis or angioedema demanding immediate care.

What precautions apply to Talimogene Laherparepvec?

Imlygic should be used under the supervision of a qualified oncologist with awareness of specific safety considerations.

- Patient selection: restrict use to adults with unresectable stage IIIB–IV melanoma. - Immunosuppression: avoid in patients receiving systemic immunosuppressive therapy. - Live vaccines: do not administer live vaccines concurrently. - Monitoring: observe for signs of infection or severe inflammatory reactions after injection. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

What does Talimogene Laherparepvec interact with?

Imlygic may interact with other agents that affect immune function or viral replication.

Major Interactions (Avoid): - Systemic corticosteroids: may reduce viral efficacy and immune activation. - Antiviral medications (e.g., acyclovir): can inhibit viral replication. - Concurrent chemotherapy: may increase risk of severe infection. - Immunosuppressive biologics: could diminish therapeutic effect. - Live attenuated vaccines: risk of uncontrolled viral replication.

Moderate Interactions (Monitor Closely): - Other immunomodulators: monitor immune response and infection signs. - Anticoagulants: watch for bleeding at injection sites. - NSAIDs: may mask fever related to viral activity.

Frequently asked questions

What is Imlygic used for?+
Imlygic is indicated for the treatment of adults with unresectable stage IIIB, IIIC, or IV melanoma. It is administered directly into tumor lesions to promote local tumor destruction and to stimulate a systemic immune response against melanoma cells.
How does Talimogene laherparepvec work?+
Talimogene laherparepvec is a genetically engineered herpes simplex virus that replicates selectively within cancer cells. As the virus lyses the tumor cells, it releases GM‑CSF, a protein that attracts and activates immune cells, thereby enhancing the body’s own anti‑tumor immunity.
What is the usual dose of Imlygic?+
The dosing regimen for Imlygic is individualized by the treating oncologist based on tumor characteristics and patient factors. The prescriber determines the volume and frequency of intralesional injections according to the approved label and clinical guidelines.
Is Imlygic safe during pregnancy or breastfeeding?+
Safety of Imlygic in pregnancy and lactation has not been established. Because it contains a live, genetically modified virus, it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, as decided by the physician.
How do I order Imlygic from GNH USA?+
To request Imlygic, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.
How does Imlygic compare with other melanoma treatments?+
Imlygic differs from conventional systemic therapies such as checkpoint inhibitors or targeted kinase inhibitors because it is delivered directly into tumor lesions and uses an oncolytic virus to trigger local and systemic immunity. It is often considered when surgery is not possible and can be combined with other immunotherapies for synergistic effect.
What are the storage and handling requirements for Imlygic?+
Imlygic must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.
How is Imlygic administered?+
Imlygic is given as an intralesional injection directly into measurable melanoma lesions. The injection is performed by a qualified healthcare professional under aseptic conditions, typically in a clinical setting, and the volume injected is based on lesion size and treatment protocol.
What are the most serious risks associated with Imlygic?+
Serious risks include cellulitis or other severe infections at the injection site, herpetic keratitis affecting the eye, disseminated viral infection especially in immunocompromised patients, and rare severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these events.
Who should not receive Imlygic?+
Imlygic is contraindicated in patients with active systemic infections, those receiving systemic immunosuppressive therapy, individuals with known hypersensitivity to any component of the product, and patients who have received live attenuated vaccines within four weeks prior to treatment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Talimogene Laherparepvec
Route
Intralesional Use
Manufacturer
Amgen Europe B.V.
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU